EUROPEAN STUDY GROUP FOR PANCREATIC CANCER - TRIAL 4. Combination versus single agent chemotherapy in resectable pancreatic ductal and peri-ampullary cancers
Phase of Trial: Phase III
Latest Information Update: 03 Nov 2017
At a glance
- Drugs Capecitabine (Primary) ; Gemcitabine
- Indications Pancreatic cancer
- Focus Therapeutic Use
- Acronyms ESPAC-4
- 02 Nov 2017 Status changed from recruiting to completed.
- 07 Jun 2016 Results assessing survival presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 04 Dec 2015 Accrual to date is 64% according to United Kingdom Clinical Research Network.